Juno Therapeutics Inc. (JUNO) was a big mover last session, as its shares rose over 15% on the day. The upside was driven by the signing of a 10-year licensing agreement with Celgene Corp. This also led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company since Jun 5, as the stock is now down nearly 2%.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Juno Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Another favorably-ranked biomedical stock is Cambrex Corporation. (CBM) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment